Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 18, Issue 5, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2022.2072143
Keywords
Systemic lupus erythematosus; lupus nephritis; belimumab; immunosuppressives
Categories
Ask authors/readers for more resources
Advances in the treatment and management of systemic lupus erythematosus have improved patient outcomes, but lupus nephritis remains a major complication. Belimumab has been shown to be superior as an add-on therapy for lupus nephritis, and personalized treatment options are expected with the development of new therapeutic agents.
In recent years, advances in the treatment and management of patients with systemic lupus erythematosus (SLE) have improved their life expectancy and quality of life. However, lupus nephritis (LN) still represents a major life-threatening complication of the disease. Belimumab (BEL), a fully human monoclonal IgG1 lambda antibody neutralizing soluble B cell activating factor, was approved more than ten years ago as add-on therapy in adults and pediatric patients with a highly active, autoantibody-positive disease despite standard of care (SoC). Recently, the superiority of the addition of BEL to SoC was also demonstrated in LN. In this review, we provide a comprehensive overview of the study landscape, available therapeutic options for SLE (focusing on BEL in renal and non-renal SLE), and new perspectives in the treatment field of this disease. A personalized treatment approach will likely become available with the advent of novel therapeutic agents for SLE and LN.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available